Nusinersen Effect on Ambulatory Function of Patients with Late-onset, Chronic SMA: A Multicenter, Prospective and Retrospective Observational Study
Phase of Trial: Phase IV
Latest Information Update: 06 Mar 2019
Price : $35 *
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- 06 Mar 2019 Status changed from not yet recruiting to recruiting.
- 31 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 7 Dec 2018.
- 12 Dec 2018 New trial record